FDA may ask Novavax to conduct additional trials of its Covid-19 vaccine to receive full approval
The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 vaccine as a post-approval commitment, a source familiar with the matter told CNN.
The terms need to be negotiated before Novavax's vaccine could be granted full approval, the source said, declining to be named because they weren't authorized to speak on behalf of the FDA.
Novavax had anticipated full approval of its vaccine by April 1, but the FDA delayed the decision because it sought more data, a source told CNN at the time.
'We can confirm we have responded to the FDA's Post Marketing Commitment (PMC) request and are awaiting feedback from the agency,' Novavax said in a statement Friday. 'PMCs are not unusual with many approved drugs / biologics having at least one PMC or requirement. We continue to believe that our application is approvable, and we look forward to our continued engagement with the FDA about their request for a PMC and to moving to approval as soon as possible.'
A spokesperson for the US Department of Health and Human Services, the FDA's parent agency, said Friday that it 'remains committed to our promise: ensuring products are safe for the American people and grounded in gold-standard science.'
The Novavax Covid-19 vaccine, which uses more traditional protein-based technology than the newer mRNA vaccines from Pfizer/BioNTech and Moderna, has been subject to emergency use authorization since 2022. But with FDA action, it would be the third vaccine against Covid-19 to receive full FDA approval, which could provide additional reassurance to people seeking the shot.
The missed deadline came at the same time the FDA named Dr. Scott Steele acting director of the Center for Biologics Evaluation and Research, which oversees vaccine regulation, days after former director Dr. Peter Marks was forced out. In his resignation letter, Marks cited 'efforts being advanced by some on the adverse health effects of vaccination' that he called 'concerning.'
HHS Secretary Robert F. Kennedy Jr., a longtime anti-vaccine advocate, has falsely called vaccines for Covid-19 'the deadliest vaccine ever made' and more recently made misleading statements about the safety of the measles vaccine amid a deadly outbreak centered in West Texas.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Fungal concerns spark nationwide recall of Zicam, Orajel products
(WJW) – Swabs under two well-known brand names have been recalled over potential fungi-related microbial contamination. According to the Food and Drug Administration (FDA), Church & Dwight Co., Inc. is voluntarily recalling some Zicam and Orajel products because fungi could be present in the items' cotton swab components. The recalled products include all lots within expiry of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs to the consumer level. Consumers are advised to 'immediately' stop using the recalled products. Major grocery chain slashing prices for the summer 'Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries,' reads the recall alert. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' The FDA said, so far, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico, said the FDA. Brain-eating amoeba: How are people infected? Here are the specific details to check for: Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. You can view images of the recalled products in the slideshow below: 'This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall,' states the FDA on its website. Consumers can Click here or call (800) 981-4710 for refund details. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
USA Today
40 minutes ago
- USA Today
Millions of brown eggs sold recalled: See list of affected products
Millions of brown eggs sold recalled: See list of affected products Show Caption Hide Caption Cucumbers under recall Cucumbers grown in Florida are part of the latest salmonella outbreak. The FDA issued a recall after the cucumbers were linked to Bedner Growers. Fox - 13 News Almost two million dozen shell eggs were voluntarily recalled after being linked to a widespread salmonella outbreak, health officials said. According to the Centers for Disease Control and Prevention (CDC), the salmonella outbreak has been linked to 79 cases, which include 21 hospitalizations across the United States. The recall was issued on June 6 after brown cage-free eggs and brown certified organic eggs distributed by August Egg Company, and sold under different brand names and restaurants were linked to the outbreak, the Food and Drug Administration says. "FDA is working with the firm to determine if eggs were distributed elsewhere and will update the advisory as information becomes available," the FDA said on its website. Recall alert: FDA: More cucumbers, ready-to-eat products recalled in growing salmonella outbreak Eggs recalled for salmonella risk: See list of affected products August Egg Co. said consumers can identify the recalled eggs by the plant code on one side of the egg carton. They can return the eggs to the place of purchase for a refund. Consumers with questions can call the company at 1-800-710-2554, between 9 a.m. and 5 p.m. PT. Here are the products recalled with the plant code and UPC. Which brands sold recalled eggs? The eggs were sold under the following brands, according to the FDA: Clover First Street Nulaid O Organics Marketside Raleys Simple Truth Sun Harvest Sunnyside Where were the eggs sold? The recalled eggs were distributed beginning Feb. 3 across multiple retailers in nine states: Eggs with sell-by dates to June 4: Through May 15, eggs with those sell-by dates were distributed to Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less, and Ralphs stores in California and Nevada. Eggs with sell-by dates to June 19: Through May 6, eggs with those sell-by dates were distributed to Walmart locations in California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. Contributing: Mike Snider and Julia Gomez, USA TODAY Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at and follow him on X @fern_cerv_.
Medscape
44 minutes ago
- Medscape
Bipolar Depression: Choosing the Right Antipsychotic
Major depressive episodes are difficult to treat in patients with bipolar disorder I (BD-I) using traditional antidepressants. However, atypical antipsychotics can be effective in BD-I, and five FDA-approved monotherapies are discussed by Dr Joseph Goldberg, of Icahn School of Medicine at Mount Sinai, New York, NY. Dr Goldberg reports that traditional antidepressants are not overly effective in the treatment of depression in BD-I, and their use can risk destabilizing mood or exacerbating mixed features. In contrast, atypical antipsychotics have demonstrated efficacy as monotherapy for BD-I. Dr Goldberg reviews the five FDA-approved atypical antipsychotics for patients with BD-I. He then discusses the specific indications for each therapy and notes their effectiveness in treating particular comorbid features of BD-I. For example, he cites quetiapine as effective in treating anxiety, and cariprazine as beneficial for impulse control. He notes that antipsychotics, as a class, are associated with increased risk for metabolic changes, including abnormal movement disorders. However, individual agents differ in tolerability and side-effect profiles. In choosing the most appropriate agent for a given patient, Dr Goldberg advises clinicians to target the symptoms needing control, understand the therapeutic goals important to the patient, and identify the agent that has the greatest potential to meet those endpoints with the lowest risk for side effects.
